De testimonio: on the evidence for decisions about the use of therapeutic interventions

[1]  S. Pocock,et al.  More on subgroup analyses in clinical trials. , 2008, The New England journal of medicine.

[2]  N. Freemantle,et al.  Observational evidence for determining drug safety , 2008, BMJ : British Medical Journal.

[3]  F. McAlister.  Applying the Results of Systematic Reviews at the Bedside , 2008 .

[4]  S. Majumdar,et al.  Oral bisphosphonates and atrial fibrillation , 2008, BMJ : British Medical Journal.

[5]  S. Cummings,et al.  Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study , 2008, BMJ : British Medical Journal.

[6]  Peter Sandercock,et al.  Sensible approaches for reducing clinical trial costs , 2008, Clinical trials.

[7]  Stephen W Lagakos,et al.  Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.

[8]  Andrew P Grieve,et al.  25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel , 2007, Pharmaceutical statistics.

[9]  Alejandro R. Jadad,et al.  Randomized controlled trials , 2007 .

[10]  M. Clarke,et al.  Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report , 2007, Journal of the Royal Society of Medicine.

[11]  D. Moher,et al.  Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force , 2007, Annals of Internal Medicine.

[12]  Paul Glasziou,et al.  When are randomised trials unnecessary? Picking signal from noise , 2007, BMJ : British Medical Journal.

[13]  A. Oxman,et al.  Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations , 2006, Health research policy and systems.

[14]  Robert M Califf,et al.  Clinical trials bureaucracy: unintended consequences of well-intentioned policy , 2006, Clinical trials.

[15]  D. Ashby.  Bayesian statistics in medicine: a 25 year review , 2006, Statistics in medicine.

[16]  Gordon H Guyatt,et al.  Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.

[17]  S. Pocock.  When (not) to stop a clinical trial for benefit. , 2005, JAMA.

[18]  M Egger,et al.  The causes and effects of socio-demographic exclusions from clinical trials. , 2005, Health technology assessment.

[19]  D. Freedman,et al.  Invited commentary: how far can epidemiologists get with statistical adjustment? , 2005, American journal of epidemiology.

[20]  Donald A Berry,et al.  Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis , 2005, Clinical trials.

[21]  Ruth Gilbert,et al.  Infant sleeping position and the sudden infant death syndrome: systematic review of observational studies and historical review of recommendations from 1940 to 2002. , 2005, International journal of epidemiology.

[22]  K. Schulz,et al.  Multiplicity in randomised trials II: subgroup and interim analyses , 2005, The Lancet.

[23]  Ping Li,et al.  Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding , 2005, BMJ : British Medical Journal.

[24]  S. Normand,et al.  Reader's guide to critical appraisal of cohort studies: 1. Role and design , 2005, BMJ : British Medical Journal.

[25]  P. Bower,et al.  Impact of participant and physician intervention preferences on randomized trials: a systematic review. , 2005, JAMA.

[26]  Dorothea Nitsch,et al.  Statistics: Analysis and Presentation of Safety Data , 2005 .

[27]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[28]  B. Butland,et al.  Bronchodilator treatment and deaths from asthma: case-control study , 2004, BMJ : British Medical Journal.

[29]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[30]  S. Ebrahim,et al.  Mendelian randomization: prospects, potentials, and limitations. , 2004, International journal of epidemiology.

[31]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the , 2004 .

[32]  Nicholas J Wald,et al.  Teleoanalysis: combining data from different types of study , 2003, BMJ : British Medical Journal.

[33]  D. Herrington.  Hormone replacement therapy and heart disease: replacing dogma with data. , 2003, Circulation.

[34]  D. Purdie.  Statistical Methods in Medical Research, 4th edn , 2003 .

[35]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[36]  V. Beral,et al.  Evidence from randomised trials on the long-term effects of hormone replacement therapy , 2002, The Lancet.

[37]  Harlan M Krumholz,et al.  Representation of the elderly, women, and minorities in heart failure clinical trials. , 2002, Archives of internal medicine.

[38]  N McKoy,et al.  Systems to rate the strength of scientific evidence. , 2002, Evidence report/technology assessment.

[39]  J. Ioannidis,et al.  Comparison of evidence of treatment effects in randomized and nonrandomized studies. , 2001, JAMA.

[40]  R. Harbour,et al.  A new system for grading recommendations in evidence based guidelines , 2001, BMJ : British Medical Journal.

[41]  U. Goldbourt,et al.  Antihypertensive therapy and the risk of malignancies. , 2001, European heart journal.

[42]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.

[43]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[44]  David Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials , 2001, Annals of Internal Medicine.

[45]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[46]  Stephen MacMahon,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies , 2001, The Lancet.

[47]  L. Kalra,et al.  Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness , 2000, BMJ : British Medical Journal.

[48]  David R. Jones,et al.  Bayesian methods in health technology assessment: a review. , 2000, Health technology assessment.

[49]  D G Altman,et al.  Bayesians and frequentists , 1998, BMJ.

[50]  Steven Shapin,et al.  The Scientific Revolution , 1997 .

[51]  Barry Gower,et al.  Scientific Method: A Historical and Philosophical Introduction , 1996 .

[52]  N. Black.  Why we need observational studies to evaluate the effectiveness of health care , 1996, BMJ.

[53]  C. Furberg,et al.  Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. , 1993, JAMA.

[54]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[55]  S J Pocock,et al.  Domiciliary thrombolysis by general practitioners. , 1992, BMJ.

[56]  Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. , 1992, BMJ.

[57]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[58]  D P Byar,et al.  Design considerations for AIDS trials. , 1990, The New England journal of medicine.

[59]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[60]  M. Pike,et al.  Hormone-replacement therapy and heart disease. , 1987, New England Journal of Medicine.

[61]  A. Feinstein,et al.  Exclusion bias and the false relationship of reserpine and breast cancer. , 1985, Archives of internal medicine.

[62]  S. Pocock,et al.  Clinical Trials: A Practical Approach , 1984 .

[63]  A. Read,et al.  FURTHER EXPERIENCE OF VITAMIN SUPPLEMENTATION FOR PREVENTION OF NEURAL TUBE DEFECT RECURRENCES , 1983, The Lancet.

[64]  J. Dolovich,et al.  The need for extended treatment of anaphylaxis. , 1980, Canadian Medical Association journal.

[65]  R Doll,et al.  Randomised controlled trials and retrospective controls. , 1980, British medical journal.

[66]  D. Kodlin,et al.  Reserpine and breast cancer , 1978, Cancer.

[67]  R. Doll,et al.  RAUWOLFIA DERIVATIVES AND BREAST CANCER IN HYPERTENSIVE WOMEN , 1976, The Lancet.

[68]  S. Shapiro,et al.  Reserpine use in relation to breast cancer. , 1974, Lancet.

[69]  Regular Aspirin Intake and Acute Myocardial Infarction , 1974, British medical journal.

[70]  A. B. Hill.  Heberden Oration, 1965*. Reflections on the Controlled Trial , 1966 .

[71]  Hill Ab.  Reflections on controlled trial. , 1966 .

[72]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[73]  Simpson Ca.  OYSTER AND VIRUS. , 1964 .

[74]  V. Rønnov-Jessen.  Blood-volume and tolerance to pentolinium in the treatment of hypertension. , 1960, Lancet.

[75]  W. H. Wilkinson,et al.  Traumatic Retroperitoneal Rupture of Duodenum , 1954, British medical journal.